| Bioactivity | AGL-2263 is an insulin receptor and insulin-like growth factor (IGF) receptor inhibitor[1][2]. | ||||||||||||
| Target | Insulin receptor. | ||||||||||||
| Invitro | AGL-2263 (5 μM, for 1 h followed by insulin treatment for 24 h) inhibits IR and insulin could still induce phosphorylation of AKT and ERK1/2 after the IR inhibition[3]. Western Blot Analysis[3] Cell Line: | ||||||||||||
| Name | AGL-2263 | ||||||||||||
| CAS | 638213-98-6 | ||||||||||||
| Formula | C17H10N2O5 | ||||||||||||
| Molar Mass | 322.27 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Li Y, et al. GDM-associated insulin deficiency hinders the dissociation of SERT from ERp44 and down-regulates placental 5-HT uptake. Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):E5697-705. [2]. Hua Zhang, et al. Somatic cells initiate primordial follicle activation and govern the development of dormant oocytes in mice. Curr Biol. 2014 Nov 3;24(21):2501-8. [3]. Ying Han, et al. Insulin mitigates apoptosis of porcine follicular granulosa cells by downregulating BimEL. Reprod Biol. 2019 Sep;19(3):293-298. |